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A B S T R A C T
The objective of this study was to determine risk factors and outcomes of infections by multidrug-resistant
gram-negative (MDR GN) bacteria in 241 recipients of hematopoietic stem cell transplantation (HSCT). The
cumulative incidence of infections was 10.5% (95% CI, 12.0% to 25.8%), with 57% of infections occurring during
the period of severe neutropenia (neutrophil count < .1 × 106/L). In multivariate analysis, allogeneic trans-
plant and colonization with MDR GN bacteria at admission to the transplant unit were significantly associated
with an increased risk of infection. Although we observed neither transplant-relatedmortality (TRM) nor deaths
due to infections by MDR GN bacteria after autologous transplant, in the allogeneic setting a significant dif-
ference was reported in terms of overall survival (OS) and TRM between patients who developed infections
and those who did not (1-year OS, 39% versus 68%; 1-year TRM, 42% versus 19%). In multivariate analysis,
refractory disease and development of grades III to IV graft-versus-host disease (GVHD) were factors that af-
fected both TRM and OS, whereas occurrence of infections by MDR GN pathogens significantly reduced OS.
We conclude that eligibility to allogeneic HSCT in MDR GN bacteria carriers should be carefully evaluated to-
gether with all other factors that independently influence outcome (disease status, donor, and GVHD risk).
© 2017 Published by Elsevier Inc. on behalf of the American Society for Blood and Marrow Transplantation.
INTRODUCTION
Bacterial infections are 1 of the most common complica-
tions in cancer patients and in recipients of hematopoietic
stem cell transplantation (HSCT). Although published epi-
demiologic data on resistance to antibiotics are scanty and
mostly dated, important differences in infection etiology and
drug resistance exist among centers and geographic areas. In
recent years, a reduction in the incidence of gram-negative
(GN) in favor of gram-positive infections and higher rates of
multidrug-resistant (MDR) infections in south-eastern versus
north-western European regions have been observed [1].
Moreover, MDR GN infections have been recognized as 1 of
the leading cause of mortality after solid organ transplanta-
tion [2-5], whereas their epidemiology and impact on patients
with hematologic diseases and HSCT recipients have been less
studied [6-9].
Theoretically, the emergence of antimicrobial resistance
represents a challenging problem in patients undergoing HSCT
for the following reasons: (1) eligibility to transplant in pa-
tients who have acquired the bacteria before the procedure
(colonized patients or carriers); (2) risk of infection spread
into the transplant center in spite of isolation procedures,
leading to epidemic episodes (infection control); and (3) high
mortality associated with infectious complications during
the aplastic period and after the engraftment in highly
immunocompromised patients due to graft-versus-host
disease (GVHD) prophylaxis or treatments. We conducted a
study to analyze the epidemiologic, microbiologic, and clin-
ical factors associated with the acquisition of infections by
MDR GN bacteria in our transplant center, with the objective
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to determine risk factors and outcomes of these infections
in recipients of HSCT.
METHODS
Patients
In this observational retrospective study, we collected the data of all 241
consecutive patients who underwent HSCT at the Transplant Center of Udine
between January 2013 and June 2015. Two thirds of the candidates to HSCT
were treated at the Hematology Department located near the Transplant
Center, whereas one third came from centers located in the surrounding towns
(Trieste, Treviso, Padua). One hundred twenty-three patients underwent al-
logeneic HSCT and 118 autologous HSCT.
Patient and transplant characteristics are summarized in Table 1. Median
patient age was 56 years (range, 15 to 77). Lymphoma and myeloma were
the most common indication for autologous HSCT, accounting for 38% and
57% of cases, respectively, whereas 56% of patients undergoing allogeneic
HSCT were affected by acute leukemia. Advanced disease after a heavy pre-
treatment, defined as at least 2 previous therapy lines, was reported in 37%
of patients before autologous HSCT and in 68% of patients before allogene-
ic HSCT. Stem cell source was peripheral blood for all autologous transplants
and for 67% of allogeneic transplants. Reduced-intensity conditioning regi-
mens [10] were administered in 70% of the allogeneic transplants. Allogeneic
stem cells came from HLA-matched sibling donors, haploidentical donors,
and unrelated donors in 27%, 12%, and 51% of the patients, respectively. For
unrelated donors, HLA typing for HLA-A, -B, -C, and -DRB1 loci was re-
quired. Forty-five of 75 unrelated transplants (60%) were HLA-mismatched,
because at least 1 allelic or antigenic mismatch between donor and recip-
ient was present in class I.
GVHD prophylaxis consisted of cyclosporine plus 3 to 4 methotrexate
courses for HLA-matched sibling transplants, with the addition of
antithymocyte globulin Thymoglobulin (Genzyme Europe, Naarden,
Netherlands) for unrelated transplants. GVHD prophylaxis in haploidentical
transplants consisted of cyclosporine, mycophenolate mofetil, and post-
transplant cyclophosphamide. Acute GVHDwas graded according to the 1994
Consensus Conference on Acute GVHDGrading criteria [11], and chronic GVHD
was staged according to criteria developed by the National Institute of Health
[12].
Definitions
A bacterial colonization was defined as the isolation of the microorgan-
ism from any nonsterile body site (usually rectum, urine, and oral cavity) in
the absence of clinical findings of infection. A bacterial infection was defined
as the isolation of themicroorganism fromblood culture or other usually sterile
body sites in association with clinical signs of systemic inflammatory re-
sponse syndrome and after the exclusion of other possible etiologies. MDR
was defined as acquired nonsusceptibility to at least 1 agent in 3 or more an-
timicrobial categories [13]. Invasive fungal disease (IFD) was defined according
to the revised definitions by the EORTC/MSG consensus group [14].
Monitoring and Management of MDR GN Infections
At admission to the transplant unit, history of previous infections and/
or colonization was collected from all patients. Throat, nasal, and rectal swabs
and urine culture were collected at admission and were repeated when nec-
essary, as clinically required. In case of fever > 38°C, patients underwent 3
sets of blood cultures by peripheral veins and central catheters.
All patients were isolated in single rooms and received anti-infective pro-
phylaxis with intravenous levofloxacin, fluconazole, and acyclovir. Patients
with history of previous infection or colonization by MDR GN bacteria (in-
dependently of the results of swabs at admission) and patients with any
positive swabs at admission were considered as MDR GN bacteria carriers.
Hospital staff and all people who came in contact with carriers and their
body fluids had to use additional contact precautions (such as gloves and
disposable coats).
Patients who had previous infections by carbapenem-resistant Klebsi-
ella pneumoniae and were still colonized before transplant received 1 or more
courses of oral gentamicin at the dose of 80mg q.i.d. for 7 days to reach neg-
ative rectal swabs before admission [15]. If an MDR carrier developed fever
> 38°C during the neutropenia period, he or she was treated with an anti-
bacterial combination effective against the MDR GN pathogen until blood
cultures results were available.
Two antimicrobial combinations against the most common carbapenem-
resistant Enterobacteriacae were administered [16]. Pre-emptive treatment
directed to carbapenem-resistant K. pneumoniaewasmeropenem 6 g/24 hours
i.v. continuous infusion, tigecycline 200mg i.v. and then 100mg × 2/day, and
gentamicin 140 mg i.v. once daily. Antibacterial combination against MDR
Pseudomonas aeruginosa was meropenem 6 g/24 hours i.v. continuous in-
fusion or piperacillin/tazobactam 18 g i.v. continuous infusion, amikacin
20 mg/kg i.v. daily, and/or colistin 9,000,000 UI i.v. and then 4,500,000 b.i.d.
i.v. on the basis of pattern of sensitivity to antimicrobial agents of the pre-
vious isolations and severity of infection. Once diagnosis of MDR GN bacteria
infection was established, treatment followed in vitro antibacterial drugs
testing in vitro.
Amikacin, meropenem, gentamicin, and piperacillin/tazobactam dosages
were driven by regular therapeutic drug monitoring. Treatment of docu-
mented infections by MDR GN bacteria was carried on until the infection
was microbiologically eradicated, all clinical signs of infection were re-
solved, and the patient was afebrile for at least 4 consecutive days.
Surveillance Cultures
Rectal, nasal, and throat swabs and urine were inoculated into a non-
selective culture media and incubated for 24 hours. Colonies screening for
Table 1







Median age, yr (range) 58 (22-77) 52 (15-69) 56 (15-77)
Sex (male/female) 67/51 69/54 136/105
Diagnosis
Leukemia 5 (4%) 69 (56%) 74 (31%)
Lymphoma 45 (38%) 19 (15%) 64 (26%)
Multiple myeloma 67 (57%) 9 (7%) 76 (32%)
Other 1 (1%) 26 (22%) 27 (11%)
Disease status at transplant
Responsive 110 (93%) 84 (68%) 194 (80%)
Resistance/progression 8 (7%) 39 (32%) 47 (20%)
Disease phase*
Early 75 (63%) 39 (32%) 114 (47%)
Advanced 43 (37%) 84 (68%) 127 (53%)
Donor and HLA matching
HLA-identical sibling 33 (27%)
HLA-haploidentical 15 (12%)
Matched unrelated 30 (24%)
Mismatched unrelated 45 (37%)
Stem cell source
Bone marrow 118 (100%) 41 (33%) 41 (17%)
Peripheral blood 82 (67%) 200 (83%)
Conditioning
Myeloablative 118 (100%) 37 (30%) 155 (64%)
Reduced intensity 86 (70%) 86 (36%)
* Early phase, a single line of treatment before transplant; advanced phase, at least 2 lines of treatments before transplant.
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MDR GN bacteria were identified by conventional phenotypic microbio-
logic techniques (culture characteristics, Gram stain, biochemical reactions,
and susceptibility to antimicrobial agents). Antibiotic susceptibility confir-
mation was performed using both a microdilution method and standardized
criteria defined by the Clinical Laboratory Standards Institute and the Eu-
ropean Committee on Antimicrobial Susceptibility Testing. A phenotypic
resistance was determined by an increase in the minimum concentration
of antimicrobial agent required to inhibit the growth of a microbe. Stan-
dard operating procedures and robust quality control guaranteed accuracy
and reproducibility of the results.
Statistical Analyses
Data were collected in an XLS database (Microsoft Office 2010; Microsoft
Corporation, Redmond, WA) from patient medical records and reviewed by
a senior hematologist and an infective diseases consultant, and data were
imported into Stata/SE 9.0 for Windows (StataCorp, College Station, TX) for
statistical analysis. The close-out date for analysis was December 31, 2015.
Transplant-relatedmortality (TRM)was defined as death due to all causes
not related to the underlying disease. Overall survival (OS) was defined as
the time (months) from transplantation to either death or last observa-
tion. OS was described according to the Kaplan-Meier approach. Comparison
between groups was performed using the log-rank test.
The cumulative incidence method was used to estimate TRM and MDR
infection incidence accounting for the presence of competing risks. For TRM,
relapse was the competing event; for MDR GN infection incidence, death
was the competing event. We collected patient-related and transplant-
related variables and explored which patient-related and transplant-
related factors were associated with incidence of MDR GN infections, TRM,
and OS. We examined the potential association between variables and in-
cidence of MDR GN infections in the overall sample of 241 patients. We
limited the analysis of the potential association between variables and TRM
and OS to the population of allogeneic transplant recipients, because no TRM
event occurred in the group of autologous transplants.
Patient-related variables included age (as continuous variable), sex (males
versus females), underlying disease (acute leukemias, lymphoma, ormyeloma
or other diagnoses), disease status at HSCT (responsive versus resistance/
progression), and phase of transplant (early versus advanced). Transplant-
related variables included donor type (HLA-identical sibling versus unrelated
or partiallymatched), stem cell source (bonemarrow versus peripheral blood),
conditioning regimen (myeloablative versus reduced intensity), duration of
severe neutropenia (number of days with neutrophil count < .1 × 106/L, as
continuous variable), duration of severe thrombocytopenia (number of days
with platelets count < 20 × 109/L, as continuous variable), GVHD prophy-
laxis (antithymocyte globulin or not), and acute GVHD (grades 0 to II versus
III to IV). Other factors that were correlated with incidence of MDR infec-
tions, TRM, and OS were previous history of infection or colonization with
MDR GN bacteria before transplant (yes or no), colonization with MDR GN
bacteria at transplant (yes or no), infections by gram-positive bacteria (yes
or no), infections by GN bacteria sensitive to antibacterial agents (yes or no),
and proven or probable IFD (yes or no).
Univariate and multivariate Cox regression were used to estimate which
patient-related and transplant-related factors were associated with OS. Based
on the method of Fine and Gray [17], univariate and multivariable back-
ward stepwise competing-risk regressionwere used to explore which patient-
related and transplant-related factors were associated with incidence of
infections by MDR GN bacteria and TRM. This model is based on the hazard
of the subdistribution and provides a simple relationship between covariates
and cumulative incidence [17].
Multivariate analyses included all variables significant at P ≤ .10 in uni-
variate analysis. Retention in the stepwise model required the variable to
be significant at P ≤ .05 in a multivariate analysis.
RESULTS
Monitoring of Colonization and/or Infection by MDR GN
Bacteria
Eighteen of 241 patients (7%) had a previous history of col-
onization (5 patients) or infection (13 patients) by MDR GN
bacteria occurring at a median time of 135 days (range, 28
to 352) before admission. At the time of admission to the
transplant unit, 13 patients (5%) were MDR GN bacteria car-
riers: 8 patients had positive rectal swabs, 4 patients had
positive urine cultures, and 1 patient had both positive rectal
swab and urine culture. Nine of 13 patients (69%) were colo-
nized by K. pneumoniae (Table 2). Only 1 of 4 patients infected
and colonized with carbapenem-resistant K. pneumoniae had
obtained a negative rectal swab after a course of oral gen-
tamicin before entering the Transplant Center. One hundred
forty-three of 241 patients (59%) developed at least 1 infec-
tive episode due to a documented bacterial or fungal etiology:
54 patients had infections by gram-positive bacteria, 64 pa-
tients showed infections by GN bacteria, 15 patients developed
IFDs, and 10 patients presented both bacterial infections and
IFDs.
Twenty-five of 241 patients (10%) developed at least 1 in-
fective episode by MDR GN bacteria at a median of 9 days
(range, 0 to 75) after HSCT, with 57% of infections occurring
during the period of severe neutropenia (neutrophil
count < .1 × 106/L). With a median follow-up of 11 months
(range, 1 to 30) after transplant, the cumulative incidence of
infections by MDR GN pathogens was 10.5% (95% confidence
interval [CI], 12.0% to 25.8%) overall and 2.5% (95% CI, .7% to
6.7%) and 18.4% (95% CI, 12.0% to 25.8%) after autologous and
allogeneic HSCT, respectively. A documented infection by aMDR
GN bacteria with the same pattern of sensitivity to antimi-
crobial drugs occurred in 6 of 13 colonized patients (46%):
Infections developed in none of the 3 recipients of autolo-
gous transplant and in 6 of 10 recipients of allogeneic
transplant. Twenty-five patients presented 33 infective epi-
sodes. MDR GN bacteria were isolated from 13 blood cultures
(40%), 11 urine cultures (33%), 4 stool cultures (12%), and 5
broncholavage fluids (15%). The MDR GNmicroorganismwas
P. aeruginosa in 20 samples (61%), K. pneumoniae in 12 (36%),
and Escherichia coli in the remaining case (3%) (Table 2). The
pattern of sensitivity of the MDR GN bacteria to antimicro-
bial drugs is provided in the Supplementary Table 1.
Factors Associated with Development of MDR GN
Infections
Among factors related to patient and disease character-
istics, an advanced disease phase and resistant disease at
transplant significantly increased the incidence of MDR in-
fections, whereas younger age and lymphoma or myeloma
as indications for transplant were associated with a signifi-
cant reduction of MDR infection incidence (Table 3). The
factors related to transplant procedure that were signifi-
cantly (P ≤ .10) associated with the development of infections
byMDR GN bacteria were type of transplant, intensity of con-
ditioning, stem cell source, duration of severe neutropenia,
and thrombocytopenia. We did not observe any significant
correlation between donor type or GVHD occurrence andMDR
infections. Moreover, a history of previous MDR infections or
Table 2
Characteristics of Colonizations at Admission to the Transplant Center and
Infections after Transplant by MDR GN Bacteria
K. pneumoniae P. aeruginosa E. coli Total
GN MDR colonization
at transplant
Rectal swabs 7 2 0 9
Urine cultures 3 2 0 5
Throat swabs 0 0 0 0
Total sites (total
patients)
10 (9*) 4 (4) 0 14 (13*)
Site of GN MDR
infections
Blood 6 7 0 13
Lung 1 4 0 5
Gut 1 3 0 4
Urogenital 4 6 1 11
Total sites (total patients) 12 (9*) 20 (15*) 1 33 (25*)
* The number includes patients with more than 1 site of colonization or
infection.
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colonization before transplant, positive swabs at admission
to the transplant unit, and concomitant or subsequent IFDs
were significantly associated with increased infection inci-
dence. In multivariate analysis, allogeneic transplant and
colonization with MDR GN bacteria were significantly asso-
ciated with a higher risk of infections (subdistribution hazard
ratio, 18.822; 95% CI, 2.477 to 143.008; P = .005;
subdistribution hazard ratio, 8.256; 95% CI, 3.374 to 20.203;
P = .000, respectively).
Outcome
With a median follow-up of 11 months (range, 1 to 30)
after transplant, 184 of 241 patients (76%) were alive with
a 1-year OS of 79% (95% CI, 73% to 84%). In total, 57 patients
died: 30 of disease progression and 27 of transplant-related
complications. All TRM events occurred after allogeneic trans-
plant. Among 122 assessable patients after allogeneic
transplant, 51 (42%) developed acute GVHD (grades I to II in
42 patients and grades III to IV in 9 patients). We did not
observe a significant association between colonization or in-
fection by MDR GN bacteria and incidence of acute GVHD,
which occurred in 4 of 10 carriers (40%) compared with 47
of 112 noncolonized patients (42%) (P = .590) and in 9 of 21
MDR infected patients (43%) in comparison with 42 of 101
patients without MDR infection (41%) (P = .550). Moreover,
there were no significant differences in rates of grades III to
IV acute GVHD and visceral organ involvement (MDR posi-
tive patients: grades III to IV acute GVHD 2/9 [22%], gut
involvement 2/9 [22%], liver involvement 1/9 [11%]; MDR neg-
ative patients: grades III to IV acute GVHD 7/42 [17%], gut
involvement 11/42 [26%], liver involvement 8/42 [19%];
P = .504, P = .586, P = .496, respectively].
Cumulative incidence of 1-year TRMwas 0% after autolo-
gous transplant and 23% (95% CI, 16% to 32%) after allogeneic
transplant. Among the 27 patients dying of TRM, infection
by MDR GN bacteria was considered the primary cause of
death in 9 patients (33%), followed by GVHD in 6 patients,
organ toxicities in 5 patients, central nervous system hem-
orrhage in 3 patients, and other infections in 4 patients. Nine
of the 25 patients infected by MDR GNmicroorganisms died
because of the infection, with an overall infection-relatedmor-
tality rate of 36%. Deaths were due to septic shock in 4 patients
and respiratory failure secondary to pneumonia in 5 pa-
tients. P. aeruginosa and K. pneumoniae equally contributed
to mortality (5 and 4 deaths, respectively).
Because neither TRM events nor deaths due to MDR in-
fections occurred after autologous transplant, we focused our
analysis on factors affecting the outcome only in the setting
of allogeneic transplant. There was a statistically significant
difference in terms of OS and TRM between patients who de-
veloped MDR GN infections after allogeneic HSCT and those
who did not (1-year OS, 39% versus 68%; 1-year TRM, 42%
versus 19%; log-rank test P = .014; Gray test P = .003) (Figures 1
and 2). In univariate analysis, factors significantly associ-
ated with TRMwere resistant disease at transplant (P = .002),
duration of severe neutropenia (P = .005), development of
Table 3
Univariate Analysis of Risk Factors for Incidence of Infections by MDR GN
Bacteria
Risk Factor SHR 95% CI P
Sex
Male 1 .916-4.516 .081
Female 2.034
Median age at transplant (yr)




Other diagnosis .184 .079-.424 .000
Disease status
Responsive 1 1.125-5.790 .025
Resistant 2.552
Disease phase*
Early 1 1.003-5.687 .049
Advanced 2.390
Procedure
Autologous transplant 1 2.301-26.015 .001
Allogeneic transplant 7.737
Preparative regimen
Myeloablative 1 1.340-6.573 .007
Reduced intensity 2.966
Stem cell source
Bone marrow 1 .182-.958 .039
Peripheral blood .417
Median days of
neutrophils < .1 × 106/L modeled as
continuous variable
1.174 1.107-1.246 .000
Median days of platelets < 20 × 109/L
modeled as continuous variable
1.051 1.023-1.080 .000
Donor
HLA-identical sibling 1 .409-2.725 .911
Unrelated or partially matched 1.056
GVHD prophylaxis
No ATG 1 .375-2.132 .802
ATG .894
Acute GVHD
Grades 0-II 1 .449-2.474 .903
Grades III- IV 1.054
Infections or colonizations with MDR
GN bacteria before transplant
No 1 3.849-20.904 .000
Yes 8.971
Colonizations with MDR GN bacteria
at transplant
No 1 2.808-17.178 .000
Yes 6.945
Non-MDR GN infections
No 1 .587-3.555 .423
Yes 1.444
GP infections
No 1 .734-3.664 .227
Yes 1.640
Proven/probable IFD
No 1 1.733-9.880 .001
Yes 4.137
SHR indicates subdistribution hazard ratio; ATG, antithymocyte globulin; GP,
gram-positive.
* Early phase, a single line of treatment before transplant; advanced phase,
at least 2 lines of treatments before transplant.
Figure 1. OS according to infections by MDR GN bacteria after allogeneic
stem cell transplantation (allo-SCT) (P = .014).
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grades III to IV acute GVHD (P = .012), need for secondary
treatment for acute GVHD (P = .014), development of infec-
tions by MDR GN bacteria (P = .000), and diagnosis of IFD
(P = .057). The variables that showed a significant associa-
tion with OS in the univariate analysis were leukemia as
underlying hematologic disease (P = .055), resistant disease
at transplant (P = .000), duration of severe neutropenia
(P = .001), development of grades III to IV acute GVHD
(P = .033), need for secondary treatment of acute GVHD
(P = .001), history of previous infections or colonization by
MDR GN bacteria before transplant (P = .012), positive swabs
at admission (P = .035), and MDR infections after transplant
(P = .014). Inmultivariate analysis, a refractory disease at trans-
plant and development of grades III to IV acute GVHD were
factors that independently affected both TRM and OS after
allogeneic transplant, whereas occurrence of MDR infec-
tions significantly reduced OS (Table 4).
DISCUSSION
Antimicrobial resistance among GN bacteria isolated in
hospitalized patients is a growing problem, with a hetero-
geneous distribution around the world. This phenomenon has
reached Northern Italy only in recent years [18], with a few
cases identified recently in our hospital. The emergence of
MDR GN bacteria among some HSCT candidates and the risk
of spread in the transplant unit have led us to develop a strict
program for infection control. The protocol was based on (1)
identification of all MDR GN bacteria carriers before admis-
sion to the transplant unit, (2) increased contact precautions
in colonized and/or infected patients, and (3) prompt treat-
ment with antimicrobial associations of all febrile episodes
in MDR GN bacteria carriers, stopping the treatment in case
of negative microbiologic cultures.
At the time of admission, colonization was identified in
5% of patients. Rectal swabs weremore informative than urine
cultures and identified K. pneumoniae more often than P.
aeruginosa. We tried to decolonize patients with swabs pos-
itive for carbapenem-resistant K. pneumoniae, but only 1 of
4 patients reached negativity, confirming that this treat-
ment cannot represent a standard practice and needs to be
investigated further. The incidence of infections by MDR GN
bacteria was 10% after transplant, with most infections oc-
curring before engraftment. Forty six percent of patients with
positive swabs at transplant developed an overt infection, con-
firming the infection rate observed by a recent Italian survey
in patients colonized with carbapenem-resistant K.
pneumoniae undergoing HSCT [19]. Factors predictive for risk
of infection byMDR GN bacteria in multivariate analysis were
allogeneic transplant and colonization at transplant. The as-
sociation with allogeneic transplant probably reflects the
clinical characteristics of recipients of this procedure, who
were more likely affected by acute leukemias and were more
often heavily pretreated comparedwith patients receiving au-
tologous transplant. Moreover, these patients weremore likely
exposed to antimicrobial drugs before transplant and had
more severe immunosuppression and alteration of the en-
dogenous flora, which increased the susceptibility to different
pathogens.
Figure 2. Cumulative incidence of TRM according to infections by MDR GN bacteria after allo-SCT (P = .003).
Table 4
Multivariate Analysis of Risk Factors for TRM and OS
TRM OS
Factor HR P 95% CI HR P 95% CI
Disease status at transplant:
Responsive 1 .006 1.386-6.938 1 .001 1.649-6.011
Refractory/progressive 3.101 3.148
Acute GVHD
Grades 0-II 1 .000 2.187-10.108 1 .033 1.085-6.640
Grades III-IV 4.702 2.685
Infections by MDR GN bacteria after transplant
No 1 .006 1.344-5.657
Yes 2.757
HR indicates hazard ratio.
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Development of infections by MDR GN bacteria had no
impact on the outcome of autologous HSCT recipients, because
the few episodes resolved without clinical consequences. In
contrast, MDR infections significantly increased TRM and
reduced OS of allogeneic HSCT recipients, being an indepen-
dent predictor for poor OS. We found that development of
infections by MDR GN microorganisms was an independent
risk factor for mortality, along with other well-known pre-
dictors for negative transplant outcome, such as active disease
and severe acute GVHD. Moreover, in our study the rates and
severity of acute GVHD were similar in patients with and
without colonization or infection by MDR GN bacteria, dif-
ferently fromwhat reported by Bilinski et al. [20], who found
that gut colonization with antibiotic-resistant bacteria pre-
disposed to more frequent and severe GVHD, especially of the
gastrointestinal tract.
Our results may support the position of some transplant
experts, who do not consider MDR GN bacteria coloniza-
tion “per se” a contraindication to allogeneic transplant [21].
In fact, eligibility to transplant in patients who have ac-
quired the pathogen before the procedure should be evaluated
in the context of all other factors known to influence the
outcome, such as disease status, HLA-matching of donor, and
risk for acute GVHD, to weigh the overall risk-to-benefit ratio
of performing HSCT. Because deaths secondary to MDR in-
fections were more common before engraftment, in clinical
practice if we plan a transplant in MDR GN bacteria carri-
ers, we should adopt all measures to speed up neutrophil
engraftment, such as use of peripheral blood stem cells, in-
fusions of a large amount of cells, and reduced-intensity
conditioning, even if thesemeasures have not yet been proven
to reduce mortality .
A comparison of our infection-related mortality rate with
previously reported data is hard, because of differences in
study designs, patient populations, and MDR microorgan-
isms involved. Most published studies are on infections by
carbapenem-resistant K. pneumoniae and were collected in
intensive care units, in solid organ transplants, and in pa-
tients with hematologic malignancies [22-25]. Recently, an
Italian survey by Girmenia et al. [19] reported the outcome
of colonizations and infections by carbapenem-resistant K.
pneumoniae in recipients of HSCT. Comparing the mortality
rate reported in that survey with our study, we note a re-
duction after both autologous and allogeneic transplants (from
16% to 0% and from 64% to 36%, respectively). It can be hy-
pothesized that our infection control strategy, based on
screening of MDR carriers and administration of first-lineMDR
bacteria-targeted therapy, contributed to lower the mortal-
ity rate after transplant in comparison with patients enrolled
in a multicenter survey and treated with empirical antimi-
crobial regimens.
We acknowledge that our study has several limitations.
First, the data were collected in a single center of southern
Europe, where incidence of infections by MDR GN patho-
gens has been increasing; therefore, the results cannot be
generalized to other centers with different epidemiologic data.
Second, we studied both autologous and allogeneic trans-
plant recipients, who had different risks of infection and
mortality. However, this study suggests a positive impact of
a strict infection control strategy that every transplant center
should adopt on the basis of its own epidemiologic data.
In conclusion, in a 3-year surveillance program of MDR
infections in the HSCT setting, all eligible patients could
proceed to autologous transplant with a negligible risk of tox-
icity. In case of allogeneic transplantation, patients who
developed MDR infections had a poorer outcome than pa-
tients without infection, suggesting that eligibility to allogeneic
transplant in colonized patients should require a careful eval-
uation of the risk-to-benefit ratio.
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